Evidence map›Paper›PMID 36970353›Full record

ReviewFrontiers in cardiovascular medicine2023

Molecular mechanisms of anthracycline induced cardiotoxicity: Zebrafish come into play.

Maryam Moossavi, Xiaoguang Lu, Joerg Herrmann, Xiaolei Xu

Open access · goldFull text readReview
In one paragraph

Review in Frontiers in cardiovascular medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Maryam MoossaviDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, United States.
Xiaoguang LuDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, United States.
Joerg HerrmannDepartment of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.
Xiaolei XuDepartment of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, United States.
Mayo Clinic in Arizona · USBeijing University of Chinese Medicine · CN

Funding

Genetic Studies of Sarcomere-based Cardiac Diseases (Diversity Supplement)R01HL081753 · NHLBI · MAYO CLINIC ROCHESTER · PI XU, XIAOLEI · 2005 to 2025
$7.8M
Epicardial remodeling in cardiomyopathy and cardiac agingR01HL107304 · NHLBI · MAYO CLINIC ROCHESTER · PI Xiaolei Xu · 2011 to 2026
$6.6M
NHLBI NIH HHS R01 HL081753NHLBI NIH HHS R01 HL107304
6 · The paper itself

Abstract

Anthracyclines are among the most potent chemotherapeutics; however, cardiotoxicity significantly restricts their use. Indeed, anthracycline-induced cardiotoxicity (AIC) fares among the worst types of cardiomyopathy, and may only slowly and partially respond to standard heart failure therapies including β-blockers and ACE inhibitors. No therapy specifically designed to treat anthracycline cardiomyopathy at present, and neither is it known if any such strategy could be developed. To address this gap and to elucidate the molecular basis of AIC with a therapeutic goal in mind, zebrafish has been introduced as an

Indexed as

anthracyclinesapoptosiscardiotoxicitymitochondriazebrafish

Identifiers

PMID36970353
PMCPMC10036604
OpenAlexW4323860107

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read1
measurements read11
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.